Posts

Production problems hamper Lantheus bid for FDA approval of LNTH-2501 radiopharma diagnostic kit

on

Lantheus mulls potential $7B sale after Curium takeover offer – Bloomberg

on

Full-Life Technologies Raises $150M to Accelerate Clinical Assets and Manufacturing

on

Spago Nanomedical Interim Report January-March 2026

on

Scaling Radioligand Therapy: Expanding the Impact of Theranostics - Recent Developments in Precision Oncology

on

The Oncology Market: Outlook for 2026

on

Convergent Therapeutics Appoints Elizabeth L. Montgomery as Chief People Officer

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Spotlight On: Five key oncology stories to watch in 2026

on

Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026

on

Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline

on

Scaling for a New Era: The Rise of Radiopharma

on

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

on

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

on

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

on

ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis' Lutathera

on

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

on